VSV-G Antibody (F-6): sc-365019

VSV-G Antibody (F-6) is a mouse monoclonal IgG2b kappa light chain antibody that detects VSV-G protein of VSV origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). VSV-G (F-6) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. VSV-G protein, a glycoprotein located on the surface of the vesicular stomatitis virus, plays a crucial role in viral infection of host cells. VSV-G protein facilitates viral entry by mediating virus attachment to host cell membrane and promoting viral envelope fusion with endosomal membrane after endocytosis. This process enables viral RNA release into host cells for replication and translation. VSV-G protein′s structure contains specific domains that interact with host cell receptors, influencing viral infection efficiency and host immune response. VSV-G protein transport from endoplasmic reticulum to plasma membrane exhibits temperature sensitivity, making VSV-G protein valuable for studying viral behavior and entry mechanisms. VSV-G (F-6) monoclonal antibody serves as an essential tool in research exploring viral pathogenesis and dynamics of viral evolution within the Rhabdoviridae family.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

VSV-G Antibody (F-6) References:

1. Vesicular stomatitis virus G pseudotyped retrovector mediates effective in vivo suicide gene delivery in experimental brain cancer.  |  Galipeau, J., et al. 1999. Cancer Res. 59: 2384-94. PMID: 10344748
2. Fusogenic activity of vesicular stomatitis virus glycoprotein plasmid in tumors as an enhancer of IL-12 gene therapy.  |  Eslahi, NK., et al. 2001. Cancer Gene Ther. 8: 55-62. PMID: 11219494
3. The transitional ER defines a boundary for quality control in the secretion of tsO45 VSV glycoprotein.  |  Mezzacasa, A. and Helenius, A. 2002. Traffic. 3: 833-49. PMID: 12383349
4. The transmembrane domain of vesicular stomatitis virus glycoprotein suffices to anchor HIV-1 envelope gp120 expressed by a recombinant vaccinia virus.  |  Jin, Y. and Wright, SE. 2003. Int J Mol Med. 12: 11-6. PMID: 12792802
5. Recombinant lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein.  |  Pinschewer, DD., et al. 2003. Proc Natl Acad Sci U S A. 100: 7895-900. PMID: 12808132
6. dl-VSVG-LacZ, a vesicular stomatitis virus glycoprotein epitope-incorporated adenovirus, exhibits marked enhancement in gene transduction efficiency.  |  Yun, CO., et al. 2003. Hum Gene Ther. 14: 1643-52. PMID: 14633406
7. Generation and characterization of a recombinant vesicular stomatitis virus expressing the glycoprotein of Borna disease virus.  |  Perez, M., et al. 2007. J Virol. 81: 5527-36. PMID: 17376911
8. Preparation of vesicular stomatitis virus-G (VSV-G) conjugate and its use in gene transfer.  |  Miyanohara, A. 2012. Cold Spring Harb Protoc. 2012: 453-6. PMID: 22474657
9. Packaging HIV- or FIV-based lentivector expression constructs and transduction of VSV-G pseudotyped viral particles.  |  Mendenhall, A., et al. 2012. J Vis Exp. e3171. PMID: 22508377
10. Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs.  |  Girard-Gagnepain, A., et al. 2014. Blood. 124: 1221-31. PMID: 24951430
11. Intracellular transport of VSV G protein occurs in cells lacking a nuclear envelope.  |  Hanover, JA. 1988. Biochem Biophys Res Commun. 152: 469-76. PMID: 2833898
12. Transport of vesicular stomatitis virus G protein to the cell surface is signal mediated in polarized and nonpolarized cells.  |  Müsch, A., et al. 1996. J Cell Biol. 133: 543-58. PMID: 8636230

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-VSV-G Antibody (F-6) has 12 citations in a variety of scientific publications.

Primary antibodies for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

VSV-G Antibody (F-6) Specifications

Alternate Product Name: Vesicular stomatitis virus G glycoprotein (VSV-G)

Product Clone Name: F-6

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2b kappa light chain

Amino Acids: 493-511

Epitope Target: VSV-G

Epitope Species: Vesicular Stomatitis virus

Product Reactivity/Detection: VSV-G

Species Reactivity/Detection: VSV

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG_2b kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 12 citations in various scientific publications

Available Conjugates/Forms for VSV-G Antibody (F-6): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin